Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Thoracic 1

Conditions

Urinary Bladder Neoplasms 2Hormone Refractory Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Mycobacterium w vaccine × Clear all
NCT00694915 2021-08-17

STCC

Cadila Pharnmaceuticals

Phase 2 Completed
122 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00680940 2012-08-07

NSCLC

Cadila Pharnmaceuticals

Phase 2 Completed
221 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00694798 2012-05-03

STCC

Cadila Pharnmaceuticals

Phase 1 Completed
22 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated
134 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡